Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06285422 | Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) | PHASE1 | ACTIVE NOT_RECRUITING | 6 | — | — | Apr 18, 2024 | Mar 1, 2029 | Nov 28, 2025 | 3 | United States |
Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities
| Arm | Type | Description |
|---|---|---|
| SC262 Plus Chemotherapy Regimen | EXPERIMENTAL | A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC262 |
| Name | Type | Description |
|---|---|---|
| SC262 | DRUG | SC262 is an allogeneic CAR -T cell therapy |
Inclusion Criteria: 1. Male or Female Subject aged 18-80 years at the time of signing the informed consent 2. Histologic diagnosis of NHL (based on World Health Organization 2016 criteria) including: * LBCL, including Diffuse Large B Cell Lymphoma (DLBCL) not otherwise specified (NOS) (includin...